These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18721063)

  • 1. Pediatric highly active antiretroviral therapy in Africa: potential benefits of a family-centered model.
    Reddi A; Leeper SC; Sunpath H
    J Infect Dis; 2008 Sep; 198(6):938-9; author reply 939-40. PubMed ID: 18721063
    [No Abstract]   [Full Text] [Related]  

  • 2. Provision of antiretroviral therapy in South Africa: unique challenges and remaining obstacles.
    Ojikutu B; Jack C; Ramjee G
    J Infect Dis; 2007 Dec; 196 Suppl 3():S523-7. PubMed ID: 18181705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of invasive pneumococcal disease in HIV-infected children: expanding the toolbox.
    Abzug MJ; Pelton SI
    J Infect Dis; 2009 Apr; 199(8):1109-11. PubMed ID: 19265480
    [No Abstract]   [Full Text] [Related]  

  • 4. South Africa will not pay for antiretroviral therapy.
    Sidley P
    BMJ; 2001 Jun; 322(7300):1441. PubMed ID: 11408289
    [No Abstract]   [Full Text] [Related]  

  • 5. Monitoring HIV antiretroviral therapy in resource-limited settings: time to avoid costly outcomes.
    Sawe FK; McIntyre JA
    Clin Infect Dis; 2009 Aug; 49(3):463-5. PubMed ID: 19569971
    [No Abstract]   [Full Text] [Related]  

  • 6. Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women.
    Currier JS
    Clin Infect Dis; 2007 Jul; 45(2):261-2. PubMed ID: 17578789
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiretroviral therapy adherence in children: outcomes from Africa.
    Reddi A; Leeper SC
    AIDS; 2008 Apr; 22(7):906-7. PubMed ID: 18427213
    [No Abstract]   [Full Text] [Related]  

  • 8. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB; Berrisford AE; Boulle AM
    Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa.
    Hamers RL; Derdelinckx I; van Vugt M; Stevens W; Rinke de Wit TF; Schuurman R;
    Antivir Ther; 2008; 13(5):625-39. PubMed ID: 18771046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral programme cuts HIV birth rate in South Africa.
    Nurs Stand; 2009 Jul 8-14; 23(44):11. PubMed ID: 19685783
    [No Abstract]   [Full Text] [Related]  

  • 11. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy.
    Müller AD; Myer L; Jaspan H
    Clin Infect Dis; 2009 Jan; 48(1):e3-5. PubMed ID: 19025495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New trends in HIV disease worldwide.
    Laurence J
    AIDS Read; 2003 Dec; 13(12):569-70. PubMed ID: 14959689
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa.
    Schuelter-Trevisol F; Trevisol DJ; Fuchs SC
    AIDS; 2009 Apr; 23(7):871-2; author reply 872-3. PubMed ID: 19363333
    [No Abstract]   [Full Text] [Related]  

  • 14. Early antiretroviral therapy: the role of cohorts.
    Sabin CA
    Curr Opin HIV AIDS; 2009 May; 4(3):200-5. PubMed ID: 19532051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell phones: tightening the communication gap in resource-limited antiretroviral programmes?
    Lester RT; Gelmon L; Plummer FA
    AIDS; 2006 Nov; 20(17):2242-4. PubMed ID: 17086071
    [No Abstract]   [Full Text] [Related]  

  • 16. Mortality and loss to follow-up among HAART initiators in rural South Africa.
    MacPherson P; Moshabela M; Martinson N; Pronyk P
    Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):588-93. PubMed ID: 19012940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastroduodenal opportunistic infections and dyspepsia in HIV-infected patients in the era of Highly Active Antiretroviral Therapy.
    Werneck-Silva AL; Prado IB
    J Gastroenterol Hepatol; 2009 Jan; 24(1):135-9. PubMed ID: 19054257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of depression in predicting antiretroviral adherence in Ugandan parents and their children initiating HAART in the MTCT-plus family treatment model: commentary on Jayne Byakika-Tusiime et al. 2009.
    Nakimuli-Mpungu E; Musisi S
    AIDS Behav; 2009 Oct; 13(5):969-72. PubMed ID: 19662522
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India.
    Kumarasamy N; Venkatesh KK; Devaleenol B; Poongulali S; Mothi SN; Solomon S
    J Trop Pediatr; 2009 Jun; 55(3):155-9. PubMed ID: 18829638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions.
    Soriano V; Rivas P; Nuñez M
    Clin Infect Dis; 2008 Dec; 47(11):1486-9. PubMed ID: 18937578
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.